SGLT2 Inhibitors: What Do Pharmacists Need To Know?

Canagliflozin, dapagliflozin, and empagliflozin belong to the class of antihyperglycemic agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors. Their ability to lower A1C, weight, and blood pressure without causing hypoglycemia makes them appealing options in diabetes management. However, reports from the Food and Drug Administration, European Medicines Agency, and Health Canada regarding the safety of SGLT2 inhibitors warrant a discussion about the risks and benefits of these agents. This patient case will discuss key areas, some of which have led to confusion, about this new class of antihyperglycemic agents.

Developed: May 2016

Please Login or Sign Up to gain full access.